Eric Dobmeier

Eric Dobmeier is a declared insider at 7 companies (chief executive); the most frequent names are Seagen Inc., Chinook Therapeutics, Inc. and Adaptive Biotechnologies Corp. Over a trading history stretching from 20 August 2015 to 11 June 2026, the count stands at 96 filings.

Both buying and selling appear: 14 purchases worth €449k, against 24 sales worth €8.0M. Netting one side against the other leaves €7.6M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 20 share grants and 33 option exercises.

A typical purchase (the median) is worth €23k. Of 14 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 12 June 2026 with a share grant in Janux Therapeutics, Inc. The clock since the last published purchase (14 November 2023) now reads 1,072 days. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.